Three-dimensional nuclear telomere architecture is associated with differential time to progression and overall survival in glioblastoma patients

Neoplasia

Volumn 12, Issue 2, 2010, Pages 183-191

  Gadji, Macoura ^a,b   Fortin, David ^a   Tsanaclis, Ana Maria ^a   Garini, Yuval ^c   Katzir, Nir ^d   Wienburg, Yifat ^d   Yan, Ju ^a   Klewes, Ludger ^b   Klonisch, Thomas ^e   Drouin, Régen ^a   Mai, Sabine ^b  

^a UNIVERSITY OF SHERBROOKE   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c BAR ILAN UNIVERSITY   (Israel)

^d Applied Spectral Imaging   (Israel)

^e UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GLIOBLASTOMA; HIGH THROUGHPUT SCREENING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; TELOMERE; THREE DIMENSIONAL IMAGING;

EID: 76749106058     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.91752     Document Type: Article

References (34)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, and Kleihues P (2007). The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114, 97-109.
2. Louis DN, Pomeroy SL, and Cairncross JG (2002). Focus on central nervous system neoplasia. Cancer Cell 1, 125-128.
3. Krex D, Klink B, Hartmann C, von Deimling A, Pietsch T, Simon M, Sabel M, Steinbach JP, Heese O, Reifenberger G, et al. (2007). Long-term survival with glioblastoma multiforme. Brain 130, 2596-2606.
4. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, et al. (2007). Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 21, 2683-2710.
5. Wen PY and Kesari S (2008). Malignant gliomas in adults. N Engl J Med 359, 492-507.
6. Martinez R, Schackert HK, Plaschke J, Baretton G, Appelt H, and Schackert G (2004). Molecular mechanisms associated with chromosomal and microsatellite instability in sporadic glioblastoma multiforme. Oncology 66, 395-403.
7. Kleihues P and Ohgaki H (1999). Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro Oncol 1, 44-51.
8. Holland EC (2001). Gliomagenesis: genetic alterations and mouse models. Nat Rev Genet 2, 120-129.
9. Scott CB, Scarantino C, Urtasun R, Movsas B, Jones CU, Simpson JR, Fischbach AJ, and Curran WJ Jr (1998). Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06. Int J Radiat Oncol Biol Phys 40, 51-55.
10. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N,Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, et al. (2005). MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352, 997-1003.
11. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, et al. (2009). Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTCNCIC trial. Lancet Oncol 10, 459-466.
12. Riemenschneider MJ and Reifenberger G (2009). Novel insights into the pathogenesis of gliomas based on large-scale molecular profiling approaches. Curr Opin Neurol 22, 619-624.
13. Boveri T (1902). Über mehrpolige Mitosen als Mittel zur Analyse des Zellkerns. Verh Phys Med Ges Wurzbg 35, 67-90.
14. Boveri T (1914). Zur Frage der Entstehungmaligner Tumoren. Jena,Germany: Fischer.
15. Callen E and Surralles J (2004). Telomere dysfunction in genome instability syndromes. Mutat Res 567, 85-104.
16. DePinho RA and Polyak K (2004). Cancer chromosomes in crisis. Nat Genet 36, 932-934.
17. Lansdorp PM (2009). Telomeres and disease. EMBO J 28, 2532-2540.
18. Chuang TC, Moshir S, Garini Y, Chuang AY, Young IT, Vermolen B, van den Doel R, Mougey V, Perrin M, Braun M, et al. (2004). The three-dimensional organization of telomeres in the nucleus of mammalian cells. BMC Biol 2, 12.
19. De Vos WH, Hoebe RA, Joss GH, HaffmansW, Baatout S, Van Oostveldt P, and Manders EM (2009). Controlled light exposure microscopy reveals dynamic telomere microterritories throughout the cell cycle. Cytometry A 75, 428-439.
20. Louis SF, Vermolen BJ, Garini Y, Young IT, Guffei A, Lichtensztejn Z, Kuttler F, Chuang TC, Moshir S, Mougey V, et al. (2005). c-Myc induces chromosomal rearrangements through telomere and chromosome remodeling in the interphase nucleus. Proc Natl Acad Sci USA 102, 9613-9618.
21. Mai S and Garini Y (2005). Oncogenic remodeling of the three-dimensional organization of the interphase nucleus: c-Myc induces telomeric aggregates whose formation precedes chromosomal rearrangements. Cell Cycle 4, 1327-1331.
22. Saito T, Hama S, Izumi H, Yamasaki F, Kajiwara Y, Matsuura S, Morishima K, Hidaka T, Shrestha P, Sugiyama K, et al. (2008). Centrosome amplification induced by survivin suppression enhances both chromosome instability and radiosensitivity in glioma cells. Br J Cancer 98, 345-355.
23. Gadji M, Fortin D, Tsanaclis AM, and Drouin R (2009). Is the 1p/19q deletion a diagnostic marker of oligodendrogliomas? Cancer Genet Cytogenet 194, 12-22.
24. Solovei I, Walter J, Cremer M, Habermann FA, and Cremer T (2002). FISH on three-dimensionally preserved nuclei. In Beatty B, Mai S, and Squire J. (Eds.), FISH A Practical Approach. New York, NY: Oxford University Press, pp. 119-157.
25. Schaefer LH, Schuster D, and Herz H (2001). Generalized approach for accelerated maximum likelihood based image restoration applied to three-dimensional fluorescence microscopy. J Microsc 204, 99-107.
26. Vermolen BJ, Garini Y, Mai S, Mougey V, Fest T, Chuang TC, Chuang AY, Wark L, and Young IT (2005). Characterizing the three-dimensional organization of telomeres. Cytometry A 67, 144-150.
27. Mai S and Garini Y (2006). The significance of telomeric aggregates in the interphase nuclei of tumor cells. J Cell Biochem 97, 904-915.
28. Guffei A, Lichtensztejn Z, Goncalves Dos Santos Silva A, Louis SF, Caporali A, and Mai S (2007). c-Myc-dependent formation of Robertsonian translocation chromosomes in mouse cells. Neoplasia 9, 578-588.
29. Guijon FB, Greulich-Bode K, Paraskevas M, Baker P, and Mai S (2007). Premalignant cervical lesions are characterized by dihydrofolate reductase gene amplification and c-Myc overexpression: possible biomarkers. J Low Genit Tract Dis 11, 265-272.
30. Knecht H, Sawan B, Lichtensztejn D, Lemieux B,Wellinger RJ, and Mai S (2009). The 3D nuclear organization of telomeres marks the transition from Hodgkin to Reed-Sternberg cells. Leukemia 23, 565-573.
31. Sawyers CL (2008). The cancer biomarker problem. Nature 452, 548-552.
32. Faria MH, Goncalves BP, do Patrocinio RM, de Moraes-Filho MO, and Rabenhorst SH (2006). Expression of Ki-67, topoisomerase IIα and c-MYC in astrocytic tumors: correlation with the histopathological grade and proliferative status. Neuropathology 26, 519-527.
33. Vaquero J, Zurita M, Coca S, and Oya S (2002). Imbalance between apostain expression and proliferative index can predict survival in primary glioblastoma. Acta Neurochir (Wien) 144, 151-155; discussion 155-156.
34. Lafuente JV, Alkiza K, Garibi JM, Alvarez A, Bilbao J, Figols J, and Cruz-Sanchez FF (2000). Biologic parameters that correlate with the prognosis of human gliomas. Neuropathology 20, 176-183.